Citadel Advisors’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Citadel Advisors’s Portfolio NRSNW Stock Details NRSNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22,711	Closed	-$7.04K	–	15249
2024 Q4	$7.04K	Sell	22,711 -2,563	-10%	-$685	﹤0.01%	13762
2024 Q3	$3.79K	Sell	25,274 -4,190	-14%	-$713	﹤0.01%	13624
2024 Q2	$6.07K	Sell	29,464 -18,674	-39%	-$4.29K	﹤0.01%	13360
2024 Q1	$20.2K	Buy	+48,138	New	+$12.1K	﹤0.01%	13010
2023 Q4	–	Sell	-11,588	Closed	-$1.85K	–	14921
2023 Q3	$1.85K	Sell	11,588 -26,346	-69%	-$4.8K	﹤0.01%	13794
2023 Q2	$8.96K	Buy	37,934 +5,323	+16%	+$1.68K	﹤0.01%	13284
2023 Q1	$9.78K	Buy	+32,611	New	+$10.4K	﹤0.01%	13562

Other funds holding NRSNW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's NRSNW Position: Q1 2025 in Review

Citadel Advisors sold out of NeuroSense Therapeutics Warrant (NRSNW) in Q1 2025, closing a stake of 22,711 shares — an estimated $7.04K sold.

Citadel Advisors first reported a position in NRSNW in Q1 2023 and held it in 7 quarters. The position peaked at $20.2K in Q1 2024. 3 funds tracked by Wall St. Rank hold NRSNW as of Q1 2025.

Citadel Advisors reported no remaining NeuroSense Therapeutics Warrant position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 22,711 NeuroSense Therapeutics Warrant shares in Q1 2025, an estimated $7.04K.
Citadel Advisors first reported a position in NeuroSense Therapeutics Warrant in Q1 2023 and held it in 7 quarters.
Citadel Advisors's NeuroSense Therapeutics Warrant position peaked at $20.2K in Q1 2024.
3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.